GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules
Phase 2
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: HBV-MPL vaccineBiological: Engerix™-B
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2008-06-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 99
- Registration Number
- NCT00697229
- Locations
- 🇧🇪
GSK Clinical Trials Call Center, Wilrijk, Belgium
Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children
Phase 3
Completed
- Conditions
- TetanusAcellular PertussisDiphtheria
- Interventions
- Biological: Infanrix™Biological: Hiberix™
- First Posted Date
- 2008-06-12
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 467
- Registration Number
- NCT00696423
- Locations
- 🇨🇳
GSK Investigational Site, Wuzhou, China
A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Biological: Influenza A (H5N1) Virus Monovalent Vaccine
- First Posted Date
- 2008-06-12
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 312
- Registration Number
- NCT00695669
- Locations
- 🇨🇦
GSK Investigational Site, Quebec, Canada
Single and Repeat Dose First Time in Human Study for an Intranasal H1/H3 Dual Antagonist in Healthy Male Subjects
- First Posted Date
- 2008-06-11
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 19
- Registration Number
- NCT00694993
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma
- First Posted Date
- 2008-06-11
- Last Posted Date
- 2017-07-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 11
- Registration Number
- NCT00695448
- Locations
- 🇺🇸
GSK Investigational Site, Houston, Texas, United States
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
Phase 2
Completed
- Conditions
- Atherosclerosis
- Interventions
- First Posted Date
- 2008-06-11
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 83
- Registration Number
- NCT00695305
- Locations
- 🇺🇸
GSK Investigational Site, Warwick, Rhode Island, United States
Single Dose Escalation Study FTIM in Order to Assess Safety and Tolerability of GSK610677
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-06-11
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT00694902
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Biological: Trivalent influenza vaccine GSK 138842ABiological: Fluarix
- First Posted Date
- 2008-06-09
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 200
- Registration Number
- NCT00693706
- Locations
- 🇺🇸
GSK Investigational Site, Lenexa, Kansas, United States
Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females
Phase 2
Completed
- Conditions
- Infections, Papillomavirus
- Interventions
- Biological: MEDI-517 HPV-16/18 VLP vaccine with Al(OH)3Biological: MEDI-517 HPV-16/18 VLP AS04 vaccineBiological: MEDI-517 HPV-16/18 VLP vaccine without adjuvant
- First Posted Date
- 2008-06-09
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT00693615
Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females
Phase 2
Completed
- Conditions
- Infections, Papillomavirus
- Interventions
- Biological: MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 2)Biological: MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 1)Biological: MEDI-517 HPV-16/18 VLP with Al(OH)3 (Formulation 4)Biological: MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 3)
- First Posted Date
- 2008-06-09
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 210
- Registration Number
- NCT00693966
© Copyright 2025. All Rights Reserved by MedPath